These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23195035)

  • 1. Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine.
    Pusic K; Aguilar Z; McLoughlin J; Kobuch S; Xu H; Tsang M; Wang A; Hui G
    FASEB J; 2013 Mar; 27(3):1153-66. PubMed ID: 23195035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies.
    Pusic K; Xu H; Stridiron A; Aguilar Z; Wang A; Hui G
    Vaccine; 2011 Nov; 29(48):8898-908. PubMed ID: 21963870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP1
    Obaldia N; Stockelman MG; Otero W; Cockrill JA; Ganeshan H; Abot EN; Zhang J; Limbach K; Charoenvit Y; Doolan DL; Tang DC; Richie TL
    Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
    Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
    Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice.
    Mehrizi AA; Rezvani N; Zakeri S; Gholami A; Babaeekhou L
    Med Microbiol Immunol; 2018 Apr; 207(2):151-166. PubMed ID: 29397427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1.
    Kumar S; Collins W; Egan A; Yadava A; Garraud O; Blackman MJ; Guevara Patino JA; Diggs C; Kaslow DC
    Infect Immun; 2000 Apr; 68(4):2215-23. PubMed ID: 10722622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HBs antigen and mannose loading on the surface of iron oxide nanoparticles in order to immuno-targeting: fabrication, characterization, cellular and humoral immunoassay.
    Rezaei M; Hosseini SN; Khavari-Nejad RA; Najafi F; Mahdavi M
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1543-1558. PubMed ID: 31007088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticles modify dendritic cell homeostasis and induce non-specific effects on immunity to malaria.
    Xiang SD; Kong YY; Hanley J; Fuchsberger M; Crimeen-Irwin B; Plebanski M
    Trans R Soc Trop Med Hyg; 2015 Jan; 109(1):70-6. PubMed ID: 25573111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies.
    Matsumoto S; Yukitake H; Kanbara H; Yamada T
    J Exp Med; 1998 Sep; 188(5):845-54. PubMed ID: 9730886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.
    Burns JM; Flaherty PR; Nanavati P; Weidanz WP
    Infect Immun; 2004 Oct; 72(10):5605-12. PubMed ID: 15385457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides.
    Hirunpetcharat C; Wipasa J; Sakkhachornphop S; Nitkumhan T; Zheng YZ; Pichyangkul S; Krieg AM; Walsh DS; Heppner DG; Good MF
    Vaccine; 2003 Jun; 21(21-22):2923-32. PubMed ID: 12798636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys.
    Egan AF; Blackman MJ; Kaslow DC
    Infect Immun; 2000 Mar; 68(3):1418-27. PubMed ID: 10678955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A hybrid multistage protein vaccine induces protective immunity against murine malaria.
    Singh B; Cabrera-Mora M; Jiang J; Moreno A
    Infect Immun; 2012 Apr; 80(4):1491-501. PubMed ID: 22252877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
    Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
    Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli.
    Dutta S; Ware LA; Barbosa A; Ockenhouse CF; Lanar DE
    Infect Immun; 2001 Sep; 69(9):5464-70. PubMed ID: 11500418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies.
    Mehrizi AA; Zakeri S; Rafati S; Salmanian AH; Djadid ND
    Parasite Immunol; 2011 Nov; 33(11):594-608. PubMed ID: 21883290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
    Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
    Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine.
    Bergmann-Leitner ES; Duncan EH; Mease RM; Angov E
    Malar J; 2012 Sep; 11():315. PubMed ID: 22958482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of nanoparticle coating on the immunogenicity of plasmid DNA vaccine encoding P. yoelii MSP-1 C-terminal.
    Shuaibu MN; Cherif MS; Kurosaki T; Helegbe GK; Kikuchi M; Yanagi T; Sasaki H; Hirayama K
    Vaccine; 2011 Apr; 29(17):3239-47. PubMed ID: 21354479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.